{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glandular-fever-infectious-mononucleosis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"4bb31918-f826-5ad9-94c9-277390a6c0a6","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field c1af2359-7c0c-4bdb-b7c5-294d2a1ff66e --><h2>Changes</h2><!-- end field c1af2359-7c0c-4bdb-b7c5-294d2a1ff66e -->","summary":null,"htmlStringContent":"<!-- begin item 6d429b2a-f449-420c-beda-deca7b350fef --><!-- begin field 63376a78-1157-4b09-9352-be5efcb11fc6 --><p><strong>March 2020 </strong>— reviewed. A literature search was conducted in February 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made, but the topic has been restructured.</p><!-- end field 63376a78-1157-4b09-9352-be5efcb11fc6 --><!-- end item 6d429b2a-f449-420c-beda-deca7b350fef -->","topic":{"id":"79787412-82dc-54ee-8f4d-82bb69926abd","topicId":"c9504b30-5339-4b0e-ae98-8637960b13dd","topicName":"Glandular fever (infectious mononucleosis)","slug":"glandular-fever-infectious-mononucleosis","lastRevised":"Last revised in March 2020","chapters":[{"id":"fe86b21c-212e-588d-8fa4-c3ba5660eac1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5f9a86f5-ef8f-544d-913a-a590a53535c1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0a089fd0-524b-5897-8e6a-ddf549b68ab1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4bb31918-f826-5ad9-94c9-277390a6c0a6","slug":"changes","fullItemName":"Changes"},{"id":"1b1796e9-9f11-5086-8044-c244b38cab9f","slug":"update","fullItemName":"Update"}]},{"id":"e8f82c54-74bc-5c96-8ae4-915ef47cdc57","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e297f8dd-9da6-5f6e-994d-22be9b9c25ce","slug":"goals","fullItemName":"Goals"},{"id":"3046ea37-29e3-531b-988d-b845fd950135","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4e842d69-8714-5155-a670-debee1452013","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6002b762-9bc1-544a-8bd4-9a17721ee873","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"91fe23ad-4802-56ea-b009-10c57fe2af06","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ff9cc4d0-961b-5fb9-9e50-cd71cb09ddb1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"41104316-b37f-5c24-a33f-610e21b30c2d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a208aaf3-91cd-5db4-a414-d800668d35fc","slug":"definition","fullItemName":"Definition"},{"id":"b7c5aaaf-3ffa-5941-bfcf-9eb30289d4eb","slug":"transmission","fullItemName":"Transmission"},{"id":"364f7cae-6906-5430-bfa6-9ad3296bd449","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a7fec36d-ff3b-5ead-aeee-30729eae51ae","slug":"complications","fullItemName":"Complications"},{"id":"e1e96b16-d495-5d31-a3dd-0b7f997675c9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"35cc3b18-c5a7-5454-945f-cc1a5cffedbe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"cfa76822-5481-564e-aa8b-2ceb86498f56","slug":"when-to-suspect-glandular-fever","fullItemName":"When to suspect glandular fever"},{"id":"8a953b4a-1996-57f6-8218-930f5cd54cfd","slug":"investigations","fullItemName":"Investigations"},{"id":"8eac8de5-26bd-5922-9d20-a425bce60c31","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"051ad3a0-73e9-53c8-890d-b540a5d79c9a","fullItemName":"Management","slug":"management","subChapters":[{"id":"b30178b8-7559-5763-9b53-da80a5c066e6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"93f8bf53-780c-5f2a-b227-a71262e777ba","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"05273e44-731a-5c3f-8f4b-d3b9e0cb29d5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"03c591a1-efa5-5fc3-ae2c-d8673f74824b","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"86912120-67f4-52e6-b125-bce8acabc24c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7018815e-d09a-5a62-8337-00be6807f631","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e8044e6c-e133-5cf3-a6a0-abef3123bc04","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"224ddc8a-471e-5b1b-8c3e-6b1e744b6d80","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74aec8a3-1f73-550b-9f3f-2020afd164b8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0a089fd0-524b-5897-8e6a-ddf549b68ab1","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"b81d4ad6-b669-568c-b769-66cf7e5472ef","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 6a74ee38-6786-4362-af5e-cb9519c0deb5 --><h3>Previous changes</h3><!-- end field 6a74ee38-6786-4362-af5e-cb9519c0deb5 -->","summary":null,"htmlStringContent":"<!-- begin item 7226c489-8287-4a9d-924c-f1f2da822672 --><!-- begin field 85e1f8e6-328e-462f-a754-d4629704a176 --><p><strong>June to July 2015 </strong>— reviewed. A literature search was conducted in June 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to the recommendations have been made.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>July 2011 </strong>— minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency (MHRA). Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>October 2009 to February 2010 </strong>— this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 85e1f8e6-328e-462f-a754-d4629704a176 --><!-- end item 7226c489-8287-4a9d-924c-f1f2da822672 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}